Dihydroberberine (GlucoVantage) vs Palmitoylethanolamide (PEA)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

Dihydroberberine (GlucoVantage)Palmitoylethanolamide (PEA)
CategorySupplementsSupplements
Standard Dose
Timing
Cycle Duration
Evidence LevelModerateStrong

Mechanism

Active metabolite of berberine with 5x greater absorption. AMPK activator that improves insulin sensitivity, reduces hepatic glucose production, and modulates gut microbiome. More bioavailable form allows lower dosing with fewer GI side effects.

Contraindications

  • Same as berberine — hypoglycemia risk with diabetic medications

Mechanism

Endocannabinoid-like lipid that activates PPAR-alpha and indirectly enhances endocannabinoid tone. Potent anti-inflammatory and analgesic without acting directly on CB1/CB2. Reduces mast cell activation, neuroinflammation, and chronic pain.

Contraindications

  • None established at standard doses

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →